Login to Your Account



Seroquel Sequel for Blues?

AstraZeneca's Mood Lifting; Targacept Gets Sunny, Too

By Randy Osborne


Monday, July 12, 2010
Targacept Inc.'s partner AstraZeneca plc last week talked up TC-5214, the adjunctive compound for major depressive disorder that just entered Phase III trials, giving nervous investors hope in the pharma giant, which will see the patent expire on Seroquel IR (quetiapine) in March 2012.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription